End-of-day quote Nasdaq  -  11-18
178.75 USD   -0.52%
2021GLOBAL MARKETS LIVE : Airbus, BP, Merck, Pfizer, Meta...
2021Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
2021ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from NASDAQ Biotechnology Index
Business Summary
Acceleron Pharma Inc. is a biopharmaceutical company. It is focused on discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on natural regulators of cellular growth and repair, mainly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. Its therapeutic areas include pulmonary and hematology. Its pulmonary program, Sotatercept, is a receptor type IIA fusion protein that is used for the treatment of patients with pulmonary arterial hypertension (PAH). ACE-1334 is a wholly owned TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Its REBLOZYL (luspatercept-aamt), is an erythroid maturation agent designed to promote red blood cell (RBC). It generates multiple Fc-fusion protein ligand traps, IntelliTrap platform technology and a pipeline of clinical and preclinical therapeutic candidates targeting mechanisms underlying serious and rare diseases.
Name Title Age Since
Rita Karachun President 60 -
Kevin McLaughlin Chief Financial Officer & Senior Vice President 64 -
Ravindra Kumar Chief Scientific Officer & Senior Vice President 61 2016
Lisa Wyman Vice President-Operations - 2019
Aaron Rosenberg Treasurer & Senior Vice President - -
Jon Filderman Secretary - -
Jerome Mychalowych Vice President-Tax - 2021
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 61,155,826 53,794,685 88.0% 0 0.0% 88.0%
Company contact information
Acceleron Pharma, Inc.
128 Sidney Street
Cambridge, MA 02139

Phone : +1.617.649.9200
Fax : +1.617.649.9988
Web :
Brand Portfolio
In partnership
More brands of Acceleron Pharma Inc.